Study the effect of 3,4-Methylenedioxy methamphetamine on cytochrome P450 2E1 activity
DOI:
https://doi.org/10.1590/s2175-97902022e20399Keywords:
MDMA, Ecstasy, Chlorzoxazone, Isolated perfused rat liver (IPRL), Rat CYP2E1Abstract
Evaluating the effects of ecstasy on CYP2E1 activity is of great concern, mainly due to growing trends in abuse and co-administration of MDMA with ethanol and the dominant role of this isoenzyme on ethanol metabolism. This study aimed to evaluate the effects of MDMA on CYP2E1 activity. A total of 24 male rats were selected and divided into three groups. The first and second groups consisted of 12 rats and were employed to optimize the perfusion method, and the third group was employed for studying the alteration of CYP2E1 activity after liver exposure to MDMA (300 and 600 ng/ml). The amount of chlorzoxazone and 6-hydroxy chlorzoxazone in a sample obtained from liver perfusion before and after exposure to a buffer containing MDMA was determined by HPLC-FL. The enzymatic activity of rat CYP2E1 decreased after liver perfusion with a buffer containing 600 ng/ml of MDMA. However, no significant changes were observed in chlorzoxazone and 6-hydroxy chlorzoxazone concentration in perfusate before and after liver perfusion with a buffer containing 300 ng/ml of MDMA. Our findings suggest that the activity of CYP2E1 in rats might decrease only after administration of MDMA at a lethal dose. However, further animal and human studies are needed to confirm our assumption.
Downloads
References
Antolino-Lobo I, Meulenbelt J, Nijmeijer SM, Scherpenisse P, van den Berg M, van Duursen MB. Differential roles of phase I and phase II enzymes in 3,4-methylendioxymethamphetamine-induced cytotoxicity. Drug Metab Dispos. 2010;38(7):1105-12.
Antolino-Lobo I, Meulenbelt J, Nijmeijer SM, Maas- Bakker RF, Meijerman I, van den Berg M, et al. 3,4-methylenedioxymethamphetamine (MDMA) interacts with therapeutic drugs on CYP3A by inhibition of pregnane X receptor (PXR) activation and catalytic enzyme inhibition. Toxicol Lett. 2011a;203(1):82-91.
Antolino-Lobo I, Meulenbelt J, van den Berg M, van Duursen MB. A mechanistic insight into 3,4-methylenedioxymethamphetamine (“ecstasy”)-mediated hepatotoxicity. Vet Q. 2011b;31(4):193-205.
Barrett SP, Darredeau C, Pihl RO. Patterns of simultaneous polysubstance use in drug using university students. Hum Psychopharmacol. 2006;21(4):255-63.
Baumann MH, Rothman RB. Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA). Int Rev Neurobiol. 2009;88:257-96.
Carvalho M, Hawksworth G, Milhazes N, Borges F, Monks TJ, Fernandes E, et al. Role of metabolites in MDMA (ecstasy)-induced nephrotoxicity: an in vitro study using rat and human renal proximal tubular cells. Arch Toxicol. 2002;76(10):581-8.
Carvalho M, Pontes H, Remiao F, Bastos ML, Carvalho F. Mechanisms underlying the hepatotoxic effects of ecstasy. Curr Pharm Biotechnol. 2010;11(5):476-95.
Conney AH, Burns JJ. Biochemical pharmacological considerations of zoxazolamine and chlorzoxazone metabolism. Ann N Y Acad Sci. 1960;86:167-77.
Docherty JR, Green AR. The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives. Br J Pharmacol. 2010;160(5):1029-44.
Downey C, Daly F, O’Boyle KM. An in vitro approach to assessing a potential drug interaction between MDMA (ecstasy) and caffeine. Toxicol In Vitro. 2014;28(2):231-9.
Ernstgard L, Warholm M, Johanson G. Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 2E1 activity. Br J Clin Pharmacol. 2004;58(2):190-200.
Gouzoulis-Mayfrank E, Daumann J. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview. J Psychopharmacol. 2006;20(2):188-93.
Han X, Parker TL. Antiinflammatory activity of cinnamon (Cinnamomum zeylanicum) bark essential oil in a human skin disease model. Phytother Res. 2017;31(7):1034-8.
Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine (“ecstasy”). Lancet. 1992;340(8816):384-7.
Jamali B, Sheikholeslami B, Hosseinzadeh Ardakani Y, Lavasani H, Rouini MR. Evaluation of the Ecstasy influence on tramadol and its main metabolite plasma concentration in rats. Drug Metab Pers Ther. 2017;32(3):137-45.
Leclercq I, Horsmans Y, Desager JP. Estimation of chlorzoxazone hydroxylase activity in liver microsomes and of the plasma pharmacokinetics of chlorzoxazone by the same high-performance liquid chromatographic method. J Chromatogr A. 1998;828(1-2):291-6.
Lieber CS. Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev. 1997;77(2):517-44.
Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2006;2(6):875-94.
Meyer MR, Du P, Schuster F, Maurer HH. Studies on the metabolism of the alpha-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC- high-resolution MS and its detectability in urine by GC-MS. J Mass Spectrom. 2010;45(12):1426-42.
Meyer MR, Peters FT, Maurer HH. The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers. Drug Metab Dispos. 2008;36(11):2345-54.
Milroy CM. “Ecstasy” associated deaths: what is a fatal concentration ? Analysis of a case series. Forensic Sci Med Pathol. 2011;7(3):248-52.
Mishin VM, Rosman AS, Basu P, Kessova I, Oneta CM, Lieber CS. Chlorzoxazone pharmacokinetics as a marker of hepatic cytochrome P4502E1 in humans. Am J Gastroenterol. 1998;93(11):2154-61.
Morefield KM, Keane M, Felgate P, White JM, Irvine RJ. Pill content, dose and resulting plasma concentrations of 3,4-methylendioxymethamphetamine (MDMA) in recreational ‘ecstasy’ users. Addiction. 2011;106(7):1293- 300.
Muzeeb S, Pasha MK, Basha SJ, Mullangi R, Srinivas NR. Effect of 1-aminobenzotriazole on the in vitro metabolism and single-dose pharmacokinetics of chlorzoxazone, a selective CYP2E1 substrate in Wistar rats. Xenobiotica. 2005;35(8):825-38.
Neyshaburinezhad N, Rouini M, Entezari H, Lavasani H, Hosseinzadeh Ardakani Y. Evaluation of changes in cytochrome P450 2C19 activity in type 2 diabetic rats before and after treatment, by using isolated perfused liver model. Iran J Basic Med Sci. 2020;23(5):629-35.
Neyshaburinezhad N, Seidabadi M, Rouini M, Lavasani H, Foroumadi A, Ardakani YH. Evaluation of hepatic CYP2D1 activity and hepatic clearance in type I and type II diabetic rat models, before and after treatment with insulin and metformin. Daru. 2020;28(2):479-487.
Neyshaburinezhad N, Rouini M, Lavasani H, H. Ardakani Y. Evaluation of Cinnamon (Cinnamomum Verum) effects on liver CYP450 2D1 activity and hepatic clearance in diabetic rats. Jundishapur J Nat Pharm Prod. 2021;16(1):e101797.
Nilchi S, Behdarvand D, Lavasani H, Rouini M, Y HA. Assessment of CYP2D6 re-activation after inhibitory effect of MDMA using tramadol as a probe. Drug Metab Pers Ther. 2018;33(3):119-25.
Palamar JJ, Kamboukos D. An examination of sociodemographic correlates of ecstasy use among high school seniors in the United States. Subst Use Misuse. 2014;49(13):1774-83.
Pontes H, Duarte JA, de Pinho PG, Soares ME, Fernandes E, Dinis-Oliveira RJ, et al. Chronic exposure to ethanol exacerbates MDMA-induced hyperthermia and exposes liver to severe MDMA-induced toxicity in CD1 mice. Toxicology. 2008;252(1-3):64-71.
Rezai, S., Neyshaburinezhad, N., Rouini, M. et al. Can combination therapy with insulin and metformin improve metabolic function of the liver, in type I diabetic patients? An animal model study on CYP2D1 activity. J Diabetes Metab Disord. 2020;19:2049-2056. https://doi.org/10.1007/ s40200-020-00678-y
» https://doi.org/https://doi.org/10.1007/ s40200-020-00678-y
Rietjens SJ, Hondebrink L, Westerink RH, Meulenbelt J. Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug-drug interactions. Crit Rev Toxicol. 2012;42(10):854-76.
Tveden-Nyborg P, Bergmann TK, Lykkesfeldt J. Basic & Clinical Pharmacology & Toxicology Policy for Experimental and Clinical studies. Basic Clin Pharmacol Toxicol. 2018;123(3):233-5.
Upreti VV, Eddington ND, Moon KH, Song BJ, Lee IJ. Drug interaction between ethanol and 3,4-methylenedioxymethamphetamine (“ecstasy”). Toxicol Lett. 2009;188(2):167-72.
Van LM, Hargreaves JA, Lennard MS, Tucker GT, Rostami-Hodjegan A. Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems. Eur J Pharm Sci. 2007;32(1):8-16.
Vollenweider FX, Liechti ME, Gamma A, Greer G, Geyer M. Acute psychological and neurophysiological effects of MDMA in humans. J Psychoactive Drugs. 2002;34(2):171- 84.
Yang J, Jamei M, Heydari A, Yeo KR, de la Torre R, Farre M, et al. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J Psychopharmacol. 2006;20(6):842-9.
Yuan R, Madani S, Wei XX, Reynolds K, Huang SM. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos. 2002;30(12):1311-9.
Yuki F, Rie I, Miki K, Mitsuhiro W, Naotaka K, Kenichiro N. Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. Eur J Pharm Sci. 2013;49(1):57-64.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
